Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analyst consensus: Ten firms give Genmab a consensus rating of "Moderate Buy" (3 Hold, 6 Buy, 1 Strong Buy) with an average 12‑month target of $39.36.
• Q4 results missed EPS: Genmab reported $0.05 EPS versus $0.46 expected while revenue matched $1.06B, with a net margin of 25.89% and ROE of 17.35%.
• Current valuation and trading: Shares opened at $28.40 (up 2.7%), market cap about $18.3B, PE ~18.3, and a one‑year range of $17.24–$35.43.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $39.3571.

A number of analysts recently commented on the company. Wall Street Zen cut Genmab A/S from a "buy" rating to a "hold" rating in a research report on Saturday, February 7th. Wolfe Research assumed coverage on Genmab A/S in a research report on Friday, March 27th. They set an "outperform" rating and a $32.00 price objective for the company. Morgan Stanley assumed coverage on Genmab A/S in a research report on Monday, February 16th. They set an "equal weight" rating and a $34.00 price objective for the company. Truist Financial upgraded Genmab A/S to a "strong-buy" rating in a research report on Wednesday, March 25th. Finally, Jefferies Financial Group began coverage on Genmab A/S in a report on Tuesday, February 17th. They set a "buy" rating and a $41.50 price target for the company.

Institutional Trading of Genmab A/S

Hedge funds have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC grew its holdings in Genmab A/S by 291.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company's stock valued at $25,000 after purchasing an additional 616 shares during the period. NewEdge Advisors LLC grew its holdings in Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company's stock valued at $38,000 after purchasing an additional 1,143 shares during the period. Brown Brothers Harriman & Co. grew its holdings in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company's stock valued at $41,000 after purchasing an additional 780 shares during the period. Founders Capital Management grew its holdings in Genmab A/S by 40.0% during the fourth quarter. Founders Capital Management now owns 1,400 shares of the company's stock valued at $43,000 after purchasing an additional 400 shares during the period. Finally, Community Bank N.A. bought a new stake in Genmab A/S during the third quarter valued at about $47,000. Institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Up 2.7%

Genmab A/S stock opened at $28.40 on Thursday. The stock has a market cap of $18.25 billion, a PE ratio of 18.32, a price-to-earnings-growth ratio of 1.24 and a beta of 0.97. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. Genmab A/S has a one year low of $17.24 and a one year high of $35.43. The stock has a fifty day moving average of $28.49 and a 200 day moving average of $30.43.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 EPS for the quarter, missing analysts' consensus estimates of $0.46 by ($0.41). The firm had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.06 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. As a group, sell-side analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.